The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The FDA expects that randomized, controlled trial data on clinical outcomes will be needed before COVID-19 vaccines can be approved for patients who are 6 months to 64 years of age and do not have ...

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

Last week saw Novavax receive full approval from the US Food and Drug Administration (FDA) for its COVID-19 vaccine, but with ...

Moderna MRNA announced that it has submitted a regulatory filing with the FDA seeking approval for an updated version of its ...

Detailed price information for Diageo Plc New Ord (DGEAF) from The Globe and Mail including charting and trades.

France has detected four cases of the new COVID-19 variant NB.1.8.1 for the first time, Anadolu Ajansi reported. Four cases ...

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

“If the FDA does not approve a vaccine for a population, then the vaccine will likely not be covered by insurers for that ...

Detailed price information for Diageo Plc New Ord (DGEAF) from The Globe and Mail including charting and trades.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...